A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

计划入组 40 人 · 首次发布于 2024 年 2 月 29 日

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

计划入组 286 人 · 首次发布于 2021 年 9 月 2 日

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

计划入组 20 人 · 首次发布于 2022 年 11 月 9 日

Mitapivat(Pyrukynd 5 Mg 4-week, Pyrukynd)

C₂₄H₂₆N₄O₃S

Scientists Win $3 Million Prize for Breakthrough Research Leading to First CRISPR Sickle Cell Therapy

Mitapivat Shows Durable Improvements in Thalassemia Patients in Phase 2 Extension Study

FDA Approves Pyrukynd (mitapivat) for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency